Nippon Chemiphar : Third Quarter Business Summary FY2022.

（TSE 4539）

FY2022 Third Quarter Business Summary

(Year Ending March 31, 2023)

Sales, Income

			FY2021				FY2022
		3Q	Distrib.	Full Year	3Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)	(Forecast1) Rate (%)
Net sales	24,727	100.0	32,506	24,015	100.0	(2.9)	32,500	73.9
Pharmaceuticals	24,004	97.1	31,501	23,295	97.0	(3.0)	―	―
Generics, proprietary products
and new drugs	21,460	86.8	28,037	20,286	84.5	(5.5)	27,300	74.3
Diagnostics	1,550	6.3	2,163	1,831	7.6	18.1	2,600	70.4
Others		722	2.9	1,004	719	3.0	(0.5)	―	―
Cost of sales		17,642	71.3	23,432	17,665	73.6	0.1	―	―
SG&A expenses	5,985	24.2	8,248	6,156	25.6	2.9	―	―
R&D expenses		1,602	6.5	2,392	1,631	6.8	1.8	2,550	64.0
Operating profit		1,099	4.4	825	192	0.8	(82.5)	300	64.2
Ordinary profit	1,152	4.7	1,022	549	2.3	(52.3)	500	109.8
Net profit attributable to
owners of parent		952	3.9	700	684	2.9	(28.1)	550	124.4

Note:

1. Revised forecast issued on January 31, 2023.
2. Issued on May 13, 2022.

(¥mn)

Initial Forecast2

Full Year Progress

(Forecast) Rate (%)

35,000	68.6
―	―
29,000	70.0
3,120	58.7
―	―
―	―
―	―
3,000	54.4
300	64.2
500	109.8
550	124.4

1

Pharmaceutical Sales

Generics, Proprietary Products and New Drugs

				FY2021				FY2022
			3Q	Distrib.	Full Year	3Q	Distrib.	YOY	Full Year	Progress
			Amount	(%)	Amount	Amount	(%)	(%)	(Forecast2)	Rate (%)
Total		21,460	100.0	28,037	20,286	100.0	(5.5)	27,300	74.3
Generics	20,075	93.5	26,283	19,253	94.9	(4.1)	25,870	74.4
	To medical institutions	19,148		25,043	18,401		(3.9)	24,870	74.0
	To other makers1		926		1,239	852		(8.0)	1,000	85.3
Proprietary products	1,385	6.5	1,754	1,033	5.1	(25.5)	1,430	72.2
	Uralyt		484		623	436		(9.9)	580	75.2
	Others		901		1,131	596		(33.8)	850	70.2
Chemiphar, ODM Generics
				FY2021				FY2022
			3Q	Distrib.	Full Year	3Q	Distrib.	YOY	Full Year	Progress
			Amount	(%)	Amount	Amount	(%)	(%)	(Forecast2)	Rate (%)
Total		20,682	100.0	27,139	20,054	100.0	(3.0)	26,880	74.6
Generics		20,075	97.1	26,283	19,253	96.0	(4.1)	25,870	74.4
Generics (ODM)		607	2.9	856	800	4.0	31.8	1,010	79.2

Note:

1. Includes exports.
2. Revised forecast issued on January 31, 2023.
3. Issued on May 13, 2022.

(¥mn)

Initial Forecast3

Full Year Progress

(Forecast) Rate (%)

29,000 70.0

27,440 70.2

26,600 69.2

1. 101.5
   1,560 66.2

1. 75.2

1. 60.9

(¥mn)

Initial Forecast3

Full Year Progress

(Forecast) Rate (%)

28,450	70.5
27,440	70.2
1,010	79.2

2

Sales Distribution

By Launch Year						(¥mn)
		FY2021		FY2022
		3Q	Distrib.	3Q	Distrib.	YOY
		Amount	(%)	Amount	(%)	(%)
FY2015 and before		16,324	81.3	15,310	79.5	(6.2)
FY2016		503	2.5	455	2.4	(9.5)
FY2017		1,201	6.0	1,195	6.2	(0.5)
FY2018		601	3.0	570	3.0	(5.1)
FY2019		106	0.5	101	0.5	(4.0)
FY2020		1,053	5.2	1,008	5.2	(4.2)
FY2021	285	1.4	335	1.7	17.6
FY2022		―	―	275	1.4	―
Total	20,075	100.0	19,253	100.0	(4.1)

By Main Therapeutic Categories

Cardiovascular and respiratory drugs

Agents affecting metabolism

Digestive organ drugs

Drugs for nervous system, sensory organs

Antibiotics and chemotherapeutic drugs

Antineoplastic agents

Others

FY2021

3Q

Distrib.

28.0

14.8

15.8

13.2

6.4

2.3

19.5

(%)

FY2022

3Q

Distrib.

27.0

17.2

15.4

13.5
4.4
1.9
20.6	3

Balance Sheet, per Share Information

Balance Sheet Data

Total assets

Net assets

Owned capital Capital-to-asset ratio (%)

Current assets

Current liabilities

Current ratio (x)

Per Share Information

March 31,2022

Amount

49,453

18,501

18,484

37.4

33,495

16,750

2.00

(¥mn)

December 31, 2022

Amount Change

50,035	582
19,171	669
19,154	669

1. 0.9
   34,621 1,125
   15,381 (1,368)

1. 0.25

(¥)

Earnings per share

Book value per share

Dividend per share

Dividend payout ratio (%)

FY2021

3Q	Full Year
Amount	Amount

264.15 194.33

	Dec. 31,		March 31,
2021	2022
5209.15	5119.99
	―	50.00
	―	25.7

	FY2022
3Q		Full Year
Amount	YOY	(Forecast)
189.62	(74.53)	152.38
Dec. 31,		Full Year
2022		(Forecast)
5307.03	97.88	―
―	―	50.00
―	―	32.8

4